Insulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023Business Wire • 01/12/23
Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 ControllerBusiness Wire • 11/14/22
Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022Business Wire • 11/04/22
Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1)Business Wire • 11/03/22
Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout NovemberBusiness Wire • 11/01/22
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/22
Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery SystemBusiness Wire • 09/20/22
Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 DiabetesBusiness Wire • 08/22/22
Insulet Corporation (PODD) CEO Jim Hollingshead on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)Business Wire • 08/04/22
Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery SystemBusiness Wire • 08/01/22